VEGFA and kidney failure: Potential risks associated with ATMP cell therapy administration may include a progression of renal failure (by increased rhabdomyolysis), diabetic retinopathy (Proliferation due to VEGF), cardiovascular risk, and possible cancer potentiation or acceleration.